e-ISSN: 0975-1556, p-ISSN:2820-2643

Available online on www.ijpcr.com

International Journal of Pharmaceutical and Clinical Research 2024; 16(6); 43-50

Review Article

The Role of Small Intestinal Microbiota in Human Health and Disease: Current Understanding and Future Perspectives

Ojal Pratap Jadhav[1], Vaishali Choure[2]

[1]MBBS, MGM Medical College and Hospital, Aurangabad, Maharashtra

[2]Associate Professor, Department of Anaesthesiology, R.D.J.M Medical College and Hospital, Muzaffarpur, Bihar

Received: 25-03-2024 / Revised: 23-04-2024 / Accepted: 26-05-2024

Corresponding Author: Dr. Ojal Pratap Jadhav

Conflict of interest: Nil

Abstract:

The small intestine microbiota is becoming recognized as performing an important role in human health and illness. This review article investigates the composition and function of the small intestine microbiota, focusing on its role in digestion, nutritional absorption, immunological regulation, and pathogen protection. We investigated the link between microbial dysbiosis and a variety of gastrointestinal, metabolic, immune-mediated, and cognitive conditions. Therapeutic approaches such as probiotics, prebiotics, antibiotics, dietary changes, and fecal microbiota transplantation (FMT) are explored, with an emphasis on their effectiveness and safety. The paper also discusses the difficulties in investigating the small intestine microbiota, including methodological constraints and the necessity for tailored treatments. Future research directions are highlighted, with an emphasis on developing technologies and their ability to overcome current limits. This article emphasizes the significance of ongoing research to fully realize the therapeutic potential of the small intestine microbiota in clinical practice.

Keywords: Small Intestine, Microbiota, Dysbiosis, Probiotics, Fecal Microbiota Transplantation, Metagenomics.

Introduction

The human microbiota, a multifaceted community of billions of bacteria that live largely in the gastrointestinal (GI) tract, is critical for general health [1]. Bacteria, viruses, fungi, and archaea all have a role in a variety of physiological activities, including digestion, immune system regulation, and pathogen defense [2]. While most study has concentrated on the microbiota of the colon, the microbiota of the small intestine is just as significant and deserves further investigation.

The small intestine, which includes the duodenum, jejunum, and ileum, is an important part of the GI tract involved for nutrition absorption [3]. Unlike the colon, the small intestine has a shorter transit time, lower microbial population, and a more dynamic interaction with the immune system [4]. These distinguishing traits provide a distinct microbial habitat that has a substantial impact on human health. The major goal of this review paper is to provide light on the makeup, function, and clinical implications of the small intestine microbiota. We intend to present a complete summary of current knowledge about how the small intestine microbiota contributes to health and its role in various disorders. This involves investigating its role in nutrition metabolism, immunological modulation, and maintaining the intestinal barrier.

Understanding the small intestine microbiota is important for a variety of reasons. It is essential for nutritional digestion and absorption, which has an influence on general nutrition and health. Second, it is inextricably related to the immune system, helping to guard against infections and modify immunological responses [5]. Finally, dysbiosis, or microbial imbalance in the small intestine, has been linked to a variety of ailments, including IBS, SIBO, and metabolic problems [5]. This review delves into the small intestine microbiota to improve our understanding of its critical role in health and illness, presenting insights applicable to both clinical practice and research.

1. Composition of the Small Intestinal Microbiota

The small intestine supports a varied and active colony of microorganisms; however, it contains fewer germs than the colon due to its faster transit time and more acidic environment. Bacteria make up most of the microbial community here, with

Lactobacillus, Streptococcus, Enterococcus, and Bacteroides being the most common genera [6]. These microorganisms serve critical roles in a variety of physiological processes required for good health.

The microbiota of the small intestine has evolved to fit its specific environment. The proximal section (duodenum) has a lower microbial density because it receives acidic chyme from the stomach, but the distal part (ileum) has a higher concentration of germs due to its closeness to the colon. This gradient represents the varied circumstances, such as pH and oxygen levels, that exist along the small intestine [7].

1.1. Factors Influencing Microbiota Composition

Several factors shape the composition of the small intestinal microbiota, including diet, age, genetics, and environment.

1.1.1. Diet: Diet has a considerable impact on the small intestine flora. Dietary components including fiber, fat, protein, and polyphenols all have an impact on microbial diversity and abundance. For example, high-fiber diets encourage the growth of good bacteria like Bifidobacterium and Lactobacillus, which are involved in digesting complex carbohydrates into short-chain fatty acids (SCFAs), necessary for gut health [8].

1.1.2. Age: The microbiota makeup varies during a person's life. Infants' microbiotas are first molded by variables such as method of delivery (vaginal birth or cesarean section) and nutrition (breast milk or formula). As people age, their microbiota's variety, and composition change, frequently stabilizing in maturity but potentially becoming less varied in the elderly, this might influence gut function and health [9].

1.1.3. Genetics: Host genetics influence the microbial makeup of the small intestine. Genetic variations can affect immune responses, mucus production, and other variables that favor microorganisms. Certain microbial communities are more heritable than others, indicating that genetics have an impact on microbiota composition [10].

1.1.4. Environment: Environmental variables such as location, cleanliness, antibiotic usage, and lifestyle have a substantial influence on the microbiome. Individuals in various areas of the world, for example, have varied microbiota profiles that are determined by their specific environmental exposures and lifestyle choices [11].

1.2. Functional Roles of the Small Intestinal Microbiota

1.2.1. Nutrient Absorption and Metabolism: One of the key tasks of the small intestine microbiota is to help in nutrition absorption and metabolism. These microorganisms help break down complex carbs, proteins, and lipids, making them easier to absorb. They also create critical vitamins including B vitamins and vitamin K, as well as SCFAs like acetate, propionate, and butyrate, which provide energy to intestinal cells and contribute to general metabolic health [12].

1.2.2. Immune System Modulation: The small intestine microbiota affects immune system function. It promotes the growth and function of the gut-associated lymphoid tissue (GALT), which is essential for immunological surveillance and response. The microbiota interacts with immune cells, helping to mature immune responses and maintain immunological tolerance to innocuous antigens. This connection is critical for limiting inappropriate immune responses, such as allergies and autoimmune disorders [12,13].

1.2.3. Barrier Function and Pathogen Defense: The tiny intestinal microbiota helps to maintain the intestinal barrier, which is essential for avoiding pathogen and toxin transfer. Beneficial bacteria increase the synthesis of mucus and tight junction proteins, which improves barrier function. Furthermore, the microbiota fights with pathogenic microorganisms for resources and attachment sites, creating antimicrobial compounds that slow the development of dangerous bacteria [13].

1.3. Unique Microbiota in the Small Intestine

There are notable differences between the microbiota of the small intestine and other parts of the gut. The small intestine's environment, which is characterized by greater oxygen levels and more dynamic nutrition availability, supports a different microbial community in contrast to the colon, which is anaerobically dominated. The small intestine's microbiota is likewise more transitory, owing to the constant intake of food and stomach fluids [14].

This habitat favors bacteria that can withstand bile acids and variable pH values. Lactobacillus species, for example, flourish in the small intestine because of their capacity to grow in bile and their function in glucose fermentation. Similarly, Streptococcus and Enterococcus species have adapted to the small intestine's nutrient-rich and oxygen-variable environment [15]. The small intestine microbiota is a diverse and dynamic community that performs critical functions in digestion, immunological regulation, and pathogen defence. Understanding the variables that impact its composition and function is critical for creating methods to improve gut health and cure associated disorders [14, 15].

2. Methods of Studying Small Intestinal Microbiota

The tiny intestinal microbiota provides particular issues due to its inaccessibility and the necessity for accurate sample procedures. To address these problems, a variety of microbial sampling and analysis strategies have been developed. These methods can be roughly classified as sampling techniques, molecular and sequencing technologies, and analytical methodologies.

2.1. Sampling Techniques

2.1.1. Endoscopic Sampling:

During an endoscopic operation, a flexible tube equipped with a camera, known as an endoscope, is used to see the small intestine and take direct samples from particular points. Biopsies can be obtained from the mucosal lining to provide direct insight into the microbial populations that exist in various locations of the small intestine. This approach enables accurate localization and collection from specific locations, resulting in tissue samples that comprise both luminal and mucosal bacteria. Limitations include invasiveness and the need for sedation or anesthesia. Furthermore, it is restricted to clinical settings and may not be suitable for routine or large-scale investigations [16].

2.1.2. Capsule-Based Sampling: Capsule-based approaches, such as the capsule endoscope, require ingesting a small, pill-sized instrument that passes down the digestive tract, recording pictures and maybe collecting samples along the way. Specialized capsules with sampling capability can gather microbiota from various areas of the small intestine. This procedure is non-invasive, requires no anesthetic, and can sample the full length of the small intestine. However, the approach has limited control over the precise sampling area and may not provide as thorough an image of the mucosal microbiota as endoscopic biopsies [17].

2.2. Molecular and Sequencing Technologies

2.2.1. 16S rRNA Sequencing: One method that's frequently used to detect and describe bacterial populations is 16S ribosomal RNA (rRNA) sequencing. It targets the 16S rRNA gene, which is largely conserved among bacteria but has hypervariable areas that can differentiate between species. This approach is inexpensive and rapid, and it yields data on the makeup and diversity of bacterial populations. However, this approach is confined to bacterial identification, provides no information on viruses, fungi, or archaea, and has lesser resolution than whole-genome sequencing [18].

2.2.2. Metagenomics: DNA from a sample is sequenced from start to finish using a process called metagenomic sequencing. This approach gives extensive information on the microbiota, which includes bacteria, viruses, fungus, and archaea. The benefits include high-resolution data with functional gene analysis, and this approach catches the complete microbial population, not just bacteria. However, this approach is more expensive and time-consuming than 16S rRNA sequencing, and it necessitates specialized bioinformatics software for data interpretation [19].

2.3. Analytical Approaches

2.3.1. Bioinformatics: Bioinformatics is critical for evaluating the massive amounts of data produced by sequencing technology. It entails applying computer tools to process, analyze, and interpret genomic sequences, as well as identifying microbial species and possible roles. This approach allows for the integration and comparison of massive datasets. This approach also helps to identify microbial interactions and ecological trends. Challenges include the need for specialized knowledge and computing resources, as well as the richness and variety of microbial communities, which can make data interpretation difficult [20].

2.3.2. Metabolomics: Studying the tiny molecules (metabolites) that the microbiota produces is known as metabolomics. Researchers can learn more about the microbiota's functional activities and interactions with the host by examining the metabolites found in the small intestine. This approach gives information on the metabolic processes of the microbiota and aids in the correlation of microbial composition to functional results and health impacts. However, metabolite identification and quantification can be difficult, and this approach necessitates integration with other data types (e.g., metagenomics) for thorough analysis [21].

Advanced sample procedures, molecular and sequencing technology, and rigorous analytical methodologies are all required for studying the small intestine microbiota. Endoscopic and capsule-based sample methods have distinct benefits and limits, allowing researchers to select the best technique for their individual needs. Molecular methods such as 16S rRNA sequencing and metagenomics give precise information about microbial composition and function, but bioinformatics and metabolomics are essential for data analysis and interpretation. Using these techniques, researchers can improve our understanding of the small intestine microbiota and its role in health and illness, opening the path for novel treatment approaches.

3. Small Intestinal Microbiota and Health

The small intestine microbiota is crucial for human health because it participates in vital physiological processes such as digestion, immunological function, and nutrition production. The symbiotic interaction between the human and these microbes has several health advantages that are critical to general well-being.

3.1. Role in Digestion and Nutrient Absorption

One of the key tasks of the small intestine microbiota is to help in the digestion and absorption of nutrients. The microbiota helps to break down complex carbs, proteins, and lipids that human digestive enzymes cannot properly digest. For example, enzymes produced by some bacteria in the small intestine breakdown dietary fibers into short-chain fatty acids (SCFAs), which are subsequently absorbed by the host and utilized as energy sources [22]. This technique not only adds nutrients to the diet, but it also improves nutrient absorption efficiency, resulting in improved nutrition and energy balance.

3.2. Impact on the Immune System

Modulating the immune system is a key function of the small intestine microbiota. It aids in the growth and maturity of gut-associated lymphoid tissue (GALT), which is required for the immune system to respond to infections. The microbiota also regulates immunoglobulin synthesis, notably IgA, which is required for mucosal immunity. Furthermore, the microbiota interacts with immune cells, supporting a balanced immunological response that inhibits hypersensitivity to non-threatening antigens and aids in the maintenance of immune tolerance. This regulation is critical in preventing infections and lowering the risk of immune-related illnesses such allergies and autoimmune diseases [23].

3.3. Contribution to the Synthesis of Vitamins and Short-Chain Fatty Acids

The small intestine microbiota has a crucial role in the production of vital vitamins and SCFAs. Certain bacteria produce vitamins such as vitamin K and different B vitamins, including B12, folate, and biotin, which are essential for a variety of body activities such as blood clotting, energy generation, and DNA synthesis. Furthermore, the microbiota ferments dietary fibers to create SCFAs such as acetate, propionate, and butyrate, which have anti-inflammatory characteristics and act as energy sources for colonocytes, therefore improving gut health [24].

3.4. Interaction with Other Gut Microbiota

The microbial environment in the small intestine is intricate and dynamic due to the intimate interactions between it and the microbiota in other areas of the gastrointestinal tract. This connection is critical to sustaining overall gut health. For example, microbial populations in the small intestine can affect the makeup and function of the colonic microbiota by influencing nutrition availability and antimicrobial compound synthesis. Such interactions contribute to the prevention of pathogenic bacteria overgrowth and the maintenance of a healthy microbial population throughout the gut [25].

The small intestine microbiota is critical for digestion, food absorption, immunological regulation, and the production of important vitamins and SCFAs. Its symbiotic interaction with the host is critical to health maintenance, emphasizing the significance of a diversified and balanced microbiota for good physiological function. Understanding these interactions provides information on potential treatment techniques for improving gut health and avoiding illness.

4. Small Intestinal Microbiota and Disease

The small intestine microbiota is essential for sustaining health, but an imbalance in this microbial population, known as dysbiosis, can lead to a variety of disorders. Dysbiosis in the small intestine is associated with a variety of gastrointestinal, metabolic, immune-mediated, and cognitive conditions.

4.1. Gastrointestinal Disorders

4.1.1. Irritable Bowel Syndrome (IBS):

IBS is a prevalent illness characterized by stomach discomfort, bloating, and irregular bowel movements. According to studies, dysbiosis in the small intestine may play an important role in the development of IBS. Alterations in microbial composition can cause increased intestinal permeability, inflammation, and motility abnormalities. According to studies, people with IBS have lower amounts of good bacteria such as Lactobacillus and Bifidobacterium and higher quantities of possibly dangerous bacteria [26].

4.1.2. Small Intestinal Bacterial Overgrowth (SIBO):

Overgrowth of bacteria in the small intestine is known as SIBO. It can result in symptoms such as bloating, diarrhea, and malabsorption. SIBO is generally caused by altered motility, structural abnormalities, or immunological deficiencies.

Clinical trials have shown that treating SIBO with antibiotics or probiotics can considerably improve symptoms, emphasizing the significance of a healthy microbial community [26, 27].

4.1.3. Celiac Disease: Celiac disease is an autoimmune illness caused by gluten intake, resulting in intestine inflammation and damage. Dysbiosis has been seen in celiac patients, with less helpful bacteria and more pro-inflammatory bacteria. This imbalance might aggravate the immunological response to gluten. According to research, probiotics and dietary changes can help restore microbial balance and relieve symptoms [27].

4.2. Metabolic Disorders

4.2.1. Obesity: The small intestine microbiota has been linked to the development of obesity. Dysbiosis can have an impact on food energy harvesting, fat accumulation, and overall inflammatory levels. Animal studies have demonstrated that transplanting microbiota from obese to germ-free mice can cause weight increase, suggesting a causative involvement.

Human studies have also found that particular bacterial profiles are connected with obesity, and changing the microbiota by diet or probiotics may help with weight control [28].

4.2.2. Type 2 Diabetes: Insulin resistance and elevated blood sugar levels are the hallmarks of type 2 diabetes. Dysbiosis in the small intestine can cause metabolic inflammation and insulin resistance. Clinical investigations have found variations in the microbiome makeup of diabetes and non-diabetic persons, with diabetic patients having decreased microbial diversity.

Prebiotics and probiotics, two interventions targeted at rebuilding a healthy microbiome, have showed potential in improving glycemic control.

4.3. Immune-Mediated Diseases

4.3.1. Inflammatory Bowel Disease (IBD): IBD, also known as Crohn's disease and ulcerative colitis, is characterized by persistent gastrointestinal inflammation. Dysbiosis is a well-documented characteristic of inflammatory bowel disease, characterized by an imbalance of pro-inflammatory and anti-inflammatory microorganisms. Animal model studies have shown that altering the microbiota can impact disease severity, implying that treatment techniques targeting the microbiome may be effective [29].

4.3.2. Autoimmune Diseases: Autoimmune illnesses develop when the immune system erroneously assaults its own tissues. Dysbiosis in the small intestine may trigger autoimmune responses by compromising the intestinal barrier and causing systemic inflammation.

Clinical studies show that people with autoimmune disorders including rheumatoid arthritis and multiple sclerosis have changed gut microbiota patterns. Dietary modifications, probiotics, and fecal microbiota transplantation (FMT) may open up new therapy options [30].

4.4. Neuropsychological Disorders

4.4.1. Gut-Brain Axis and Mental Health: The gut-brain axis describes the bidirectional connection between the gut and the brain. Dysbiosis in the small intestine can have an influence on mental health by altering neurotransmitter and inflammatory mediator levels. Clinical investigations have discovered links between gut microbiota makeup and mental health issues like sadness and anxiety. Animal models have demonstrated that changing the gut microbiota may affect behaviour and brain function, lending credence to the microbiome's role in mental health [31].

4.4.2. Autism Spectrum Disorders (ASD):

ASD is distinguished by social communication problems and repetitive behaviours. Emerging data shows that dysbiosis of the small intestine may contribute to ASD. Studies have indicated that children with ASD have a different gut microbiome composition than neurotypical children. Animal models have demonstrated that transplanting microbiota from ASD patients to germ-free mice can cause ASD-like behaviors, indicating a possible relationship. Interventions that affect the gut microbiota, such as dietary modifications and probiotics, are being studied as possible therapies [32].

5. Therapeutic Interventions Targeting Small Intestinal Microbiota

Understanding the significance of the small intestine microbiota in health and illness has resulted in the development of a variety of therapeutic approaches targeted at influencing this complex microbial population. These therapies include probiotics and prebiotics, antibiotics and antimicrobials, dietary changes, and novel techniques such as fecal microbiota transplantation (FMT). This section evaluates existing and developing medicines, assessing their efficacy and safety.

5.1. Probiotics and Prebiotics

5.1.1. Probiotics: Probiotics are living bacteria that can provide health advantages when taken in sufficient quantities. They can help restore the equilibrium of the small intestine flora, especially in IBS and SIBO. Lactobacillus and Bifidobacterium are two popular probiotic strains that have showed potential in enhancing gut health and lowering symptoms of gastrointestinal illnesses.

Clinical studies show that probiotics can enhance gut barrier integrity, decrease inflammation, and modify immunological responses. However, their efficacy varies depending on the strain, dosage, and specific patient characteristics. Probiotics are usually regarded as harmless, with few negative effects, although their long-term influence warrants additional exploration [33].

5.1.2. Prebiotics: Prebiotics are non-digestible dietary components that promote the formation of good bacteria in the stomach. They consist of inulin, fructooligosaccharides (FOS), and galactooligosaccharides (GOS). Prebiotics stimulate the development and activity of probiotics, promoting a healthy microbiome. Prebiotics have been found to improve bowel function, increase mineral absorption, and lower the risk of several gastrointestinal illnesses. They are usually considered harmless, although excessive use might induce bloating and gas [33].

5.2. Antibiotics and Antimicrobials

5.2.1. Antibiotics: The equilibrium of the small intestine microbiota can be upset by antibiotics, which are used to treat bacterial infections. Targeted antibiotics (e.g., rifaximin) are used to treat SIBO by reducing bacterial overgrowth and alleviating symptoms. While medications might help manage SIBO, they can also contribute to antibiotic resistance and further dysbiosis. To reduce side effects, antibiotic medication should be carefully selected and restricted in length [34].

5.2.2. Antimicrobials: Natural antimicrobials, such as berberine and oregano oil, are being studied as alternatives to conventional antibiotics. They can selectively kill harmful germs while conserving healthy microorganisms. Emerging data shows that natural antimicrobials can be as effective as antibiotics while causing fewer negative effects. However, further study is required to completely prove their safety and efficacy [34].

5.3. Dietary Interventions

Diet significantly influences the small intestinal microbiome. Dietary therapies, such as low-FODMAP diets for IBS and gluten-free diets for celiac disease, can assist with symptoms and gut health. Dietary changes can be quite useful in alleviating symptoms and promoting a healthy microbiome. However, tailored dietary programs are required since individual reactions to dietary modifications might differ greatly [35].

5.4. Fecal Microbiota Transplantation (FMT)

FMT is the process of transferring fecal matter from a healthy donor to a patient in order to re-establish a balanced microbiome. It has demonstrated excellent efficacy in treating recurrent Clostridioides difficile infections and is being investigated for additional gastrointestinal and systemic disorders. FMT has shown excellent success in treating certain infections and has promise for illnesses such as IBD and metabolic disorders. However, its safety and long-term consequences are still being investigated, and standard practices are required [36].

5.5. Future Therapeutic Strategies

Emerging therapeutics for the small intestine microbiota include phage therapy, which employs bacteriophages to specifically target pathogenic bacteria, and customized microbiota-based treatments, which adapt interventions to an individual's microbiota profile. These novel techniques have enormous potential, but they will require substantial investigation to fully understand their processes, effectiveness, and safety. Personalized therapies represent a potential future in microbiota-based therapy, providing customized solutions for each patient [37].

6. Challenges and Future Directions

The intricacy and limited access of the small intestine make research on the small intestinal microbiota particularly challenging. Current technologies, such as endoscopic sampling and capsule-based procedures, can be intrusive and may fail to capture the microbiota's complete variety.

Furthermore, analytical constraints, such as the difficulties of growing specific microbes and the complexities of interpreting metagenomic data, impede our knowledge of the microbiota's entire extent and function [38]. One potential topic is customized therapy, which is based on an individual's microbiome composition. Personalized methods can improve the efficacy of probiotics, prebiotics, and nutritional therapies by addressing individual microbial imbalances. However, this necessitates a thorough examination of an individual's microbiota, and a better knowledge of how particular microbial alterations affect health [39].

Uncertainty surrounds the long-term effects of microbiota alteration, including the use of probiotics, antibiotics, and fecal microbiota transplantation (FMT). While these therapies can give immediate advantages, the long-term implications on microbiota stability and host health are still being studied.

Emerging technologies provide considerable promise for furthering microbiota research. Single cell sequencing and sophisticated bioinformatics methods can give more detailed and accurate information on microbial communities. Furthermore, advances in synthetic biology may enable the generation of designer probiotics customized to specific demands [40].

Future research should focus on overcoming present methodological constraints, understanding the long-term effects of microbiome manipulations, and using future technology to provide effective and tailored therapies.

Conclusion

The small intestine microbiota has a significant impact on health and illness, impacting digestion, immunological function, and metabolism. Further study is required to completely understand these connections and create targeted therapeutics.

Future goals should include improving research methods and investigating customized medical options. The potential for therapeutic applications is enormous, with improved treatment of a variety of gastrointestinal, metabolic, and immune-mediated diseases.

References

1. Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J. 2017 May 16; 474(11):1823-1836. doi: 10.1042/BCJ20 160510.
2. Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Nageshwar Reddy D. Role of the normal gut microbiota. World J Gastroenterol. 2015 Aug 7; 21(29):8787-803.
3. Burman A, Kaji I. Luminal Chemosensory Cells in the Small Intestine. Nutrients. 2021 Oct 22; 13(11):3712.
4. Jensen BAH, Heyndrickx M, Jonkers D, Mackie A, Millet S, Naghibi M, et al. Small intestine vs. colon ecology and physiology: Why it matters in probiotic administration. Cell Rep Med. 2023 Sep 19; 4(9):101190.
5. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014 Mar 27; 157(1):121-41.
6. Lomasney KW, Cryan JF, Hyland NP. Converging effects of a Bifidobacterium and Lactobacillus probiotic strain on mouse intestinal physiology. Am J Physiol Gastrointest Liver Physiol. 2014 Jul 15; 307(2):G241-7
7. Delbaere K, Roegiers I, Bron A, Durif C, Van de Wiele T, Blanquet-Diot S, Marinelli L. The small intestine: dining table of host-microbiota meetings. FEMS Microbiol Rev. 2023 May 19; 47(3):fuad022. doi: 10.1093/femsre/fuad022.
8. Moles L, Otaegui D. The Impact of Diet on Microbiota Evolution and Human Health. Is Diet an Adequate Tool for Microbiota Modulation? Nutrients. 2020 Jun 2; 12(6):1654.
9. Rodríguez JM, Murphy K, Stanton C, Ross RP, Kober OI, Juge N, Avershina E, Rudi K, Narbad A, Jenmalm MC, Marchesi JR, Collado MC. The composition of the gut microbiota throughout life, with an emphasis on early life. Microb Ecol Health Dis. 2015 Feb 2; 26:26050.
10. Bubier JA, Chesler EJ, Weinstock GM. Host genetic control of gut microbiome composition. Mamm Genome. 2021 Aug; 32(4):263-281.
11. Conlon MA, Bird AR. The impact of diet and lifestyle on gut microbiota and human health. Nutrients. 2014 Dec 24; 7(1):17-44.
12. Vemuri R, Gundamaraju R, Shastri MD, Shukla SD, Kalpurath K, Ball M, Tristram S, Shankar EM, Ahuja K, Eri R. Gut Microbial Changes, Interactions, and Their Implications on Human Lifecycle: An Ageing Perspective. Biomed Res Int. 2018 Feb 26; 2018:4178607.
13. Takiishi T, Fenero CIM, Câmara NOS. Intestinal barrier and gut microbiota: Shaping our immune responses throughout life. Tissue Barriers. 2017 Oct 2; 5(4):e1373208.
14. Leeming ER, Johnson AJ, Spector TD, Le Roy CI. Effect of Diet on the Gut Microbiota: Rethinking Intervention Duration. Nutrients. 2019 Nov 22; 11(12):2862.
15. Kastl AJ Jr, Terry NA, Wu GD, Albenberg LG. The Structure and Function of the Human Small Intestinal Microbiota: Current Understanding and Future Directions. Cell Mol Gastroenterol Hepatol. 2020;9(1):33-45.
16. Mehedi IM, Rao KP, Alotaibi FM, Alkanfery HM. Intelligent Wireless Capsule Endoscopy for the Diagnosis of Gastrointestinal Diseases. Diagnostics (Basel). 2023 Apr 17; 13(8):1445.
17. Ashour AS, Dey N, Mohamed WS, Tromp JG, Sherratt RS, Shi F, Moraru L. Colored Video Analysis in Wireless Capsule Endoscopy: A Survey of State-of-the-Art. Curr Med Imaging. 2020; 16(9):1074-1084.
18. Church DL, Cerutti L, Gürtler A, Griener T, Zelazny A, Emler S. Performance and Application of 16S rRNA Gene Cycle Sequencing for Routine Identification of Bacteria in the Clinical Microbiology Laboratory. Clin Microbiol Rev. 2020 Sep 9; 33(4):e00053-19.
19. Shi Y, Wang G, Lau HC, Yu J. Metagenomic Sequencing for Microbial DNA in Human Samples: Emerging Technological Advances. Int J Mol Sci. 2022 Feb 16; 23(4):2181
20. Bansal AK. Bioinformatics in microbial biotechnology--a mini review. Microb Cell Fact. 2005 Jun 28; 4:19. doi: 10.1186/1475-2859-4-19.
21. Liu J, Tan Y, Cheng H, Zhang D, Feng W, Peng C. Functions of Gut Microbiota Metabolites, Current Status and Future Perspectives. Aging Dis. 2022 Jul 11; 13(4):1106-1126.
22. Rowland I, Gibson G, Heinken A, Scott K, Swann J, Thiele I, Tuohy K. Gut microbiota functions: metabolism of nutrients and other food components. Eur J Nutr. 2018 Feb; 57(1):1-24.
23. Agace WW, McCoy KD. Regionalized Development and Maintenance of the Intestinal Adaptive Immune Landscape. Immunity. 2017 Apr 18; 46(4):532-548.
24. Den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud DJ, Bakker BM. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res. 2013 Sep; 54(9):2325-40.
25. Videhult FK, West CE. Nutrition, gut microbiota and child health outcomes. Curr Opin Clin Nutr Metab Care. 2016 May; 19(3):208-13.
26. Hayes PA, Fraher MH, Quigley EM. Irritable bowel syndrome: the role of food in pathogen-

esis and management. Gastroenterol Hepatol (N Y). 2014 Mar; 10(3):164-74.
27. Roland BC, Ciarleglio MM, Clarke JO, Semler JR, Tomakin E, Mullin GE, Pasricha PJ. Small Intestinal Transit Time Is Delayed in Small Intestinal Bacterial Overgrowth. J Clin Gastroenterol. 2015 Aug; 49(7):571-6.
28. Liu BN, Liu XT, Liang ZH, Wang JH. Gut microbiota in obesity. World J Gastroenterol. 2021 Jul 7; 27(25):3837-3850
29. Alshehri D, Saadah O, Mosli M, Edris S, Alhindi R, Bahieldin A. Dysbiosis of gut microbiota in inflammatory bowel disease: Current therapies and potential for microbiota-modulating therapeutic approaches. Bosn J Basic Med Sci. 2021 Jun 1; 21(3):270-283.
30. Wu HJ, Wu E. The role of gut microbiota in immune homeostasis and autoimmunity. Gut Microbes. 2012 Jan-Feb; 3(1):4-14.
31. Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol. 2015 Apr-Jun; 28(2):203-209.
32. Fattorusso A, Di Genova L, Dell'Isola GB, Mencaroni E, Esposito S. Autism Spectrum Disorders and the Gut Microbiota. Nutrients. 2019 Feb 28; 11(3):521.
33. Davani-Davari D, Negahdaripour M, Karimzadeh I, Seifan M, Mohkam M, Masoumi SJ, Berenjian A, Ghasemi Y. Prebiotics: Definition, Types, Sources, Mechanisms, and Clinical Applications. Foods. 2019 Mar 9;8(3):92.
34. Cho NA, Strayer K, Dobson B, McDonald B. Pathogenesis and therapeutic opportunities of gut microbiome dysbiosis in critical illness. Gut Microbes. 2024 Jan-Dec;16(1):2351478.
35. Naseri K, Dabiri H, Rostami-Nejad M, Yadegar A, Houri H, Olfatifar M, Sadeghi A, Saadati S, Ciacci C, Iovino P, Zali MR. Influence of low FODMAP-gluten free diet on gut microbiota alterations and symptom severity in Iranian patients with irritable bowel syndrome. BMC Gastroenterol. 2021 Jul 14; 21(1):292.
36. Gupta S, Allen-Vercoe E, Petrof EO. Fecal microbiota transplantation: in perspective. Therap Adv Gastroenterol. 2016 Mar; 9(2):229-39.
37. Fujiki J, Schnabl B. Phage therapy: Targeting intestinal bacterial microbiota for the treatment of liver diseases. JHEP Rep. 2023 Sep 23; 5(12):100909
38. Ruigrok RAAA, Weersma RK, Vich Vila A. The emerging role of the small intestinal microbiota in human health and disease. Gut Microbes. 2023 Jan-Dec; 15(1):2201155.
39. Kashyap PC, Chia N, Nelson H, Segal E, Elinav E. Microbiome at the Frontier of Personalized Medicine. Mayo Clin Proc. 2017 Dec; 92(12):1855-1864.
40. Arnold JW, Roach J, Azcarate-Peril MA. Emerging Technologies for Gut Microbiome Research. Trends Microbiol. 2016 Nov; 24(11):887-901.